2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 1543

Obese Patients with RA Have a More Seropositive and a More Active Disease with Less Deformities
Abstract Number: 2289

Obesity and Echocardiographic Changes in the Different Stages of Gout
Abstract Number: 2369

Obesity and Severity of Joint Space Narrowing Are Associated with Viscosupplementation Failure in Patients with Knee Osteoarthritis. Post-Hoc Analysis of a Double-Blind, Controlled, Multicentre, Randomized Trial
Abstract Number: 1171

Obesity and the Risk of Systemic Lupus Erythematosus in the Nurses’ Health Studies
Abstract Number: 2352

Obesity-Related Systemic Inflammation and Knee Synovitis
Abstract Number: 2686

Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic
Abstract Number: 983

Objectively Assessed Sedentary Behaviour and Light Physical Activity Are Associated with Long-Term Cardiovascular Risk in People Living with Rheumatoid Arthritis Independently of Moderate-to-Vigorous Physical Activity
Abstract Number: 3057

Objectively Measured Physical Activity and Risk of Knee Osteoarthritis: The Osteoarthritis Initiative
Abstract Number: 1294

Oblique Views Radiographs Have Advantages over Antero-Posterior View Radiographs in Assessing Sacroiliitis in Patients with Early Axial Spondyloarthritis
Abstract Number: 3244

Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)
Abstract Number: 318

Observer Variability of Joint Space with Measurements Is Subject Related in Medial Knee Osteoarthritis
Abstract Number: 1947

Ocular Manifestations of ANCA-Associated Vasculitis
Abstract Number: 1027

Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Abstract Number: 1887

Olfactory Impairment Is Associate with Cognitive Dysfunction and Regional Brain Atrophy in Systemic Sclerosis
Abstract Number: 1598

Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Abstract Number: 1506

One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Abstract Number: 113

Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Abstract Number: 1182

Opiod Use and Death in Chronic Pain Patients with Systemic Lupus Erythematosis
Abstract Number: 369

Opioid Prescriptions and Adverse Reactions in Children and Adolescents without Serious Diseases
Abstract Number: 1850

Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Abstract Number: 2941

Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Abstract Number: 2956

Optimization of Thiopurines with a Xanthine Oxidase Inhibitor in Patients with Autoimmune Systemic Diseases
Abstract Number: 1239

Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool
Abstract Number: 86

Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture
Abstract Number: 412

Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder
Abstract Number: 1988

Oral Health and Anti-Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis
Abstract Number: 2320

Oropharyngeal Dysphagia in Autoimmune Myositis
Abstract Number: 3097

Osteoclast Precursor Frequency and Imaging Findings Associated with Arthritis Onset in a Psoriasis Longitudinal Cohort
Abstract Number: 365

Osteonecrosis of the Femoral Head Is Associated with Low Bone Mass.
Abstract Number: 357

Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment
Abstract Number: 1796

Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 360

Osteoporosis Prevalence in Lung Transplant Patients
Abstract Number: 356

Osteoporotic Fracture As the Main Risk Factor in the Detection of Osteoporosis in Men Under 70 Years
Abstract Number: 1507

Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Abstract Number: 1386

Outcome of 847 Childhood-Onset Systemic LUPUS Erythematousus Patients in Three Age Groups
Abstract Number: 972

Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Abstract Number: 2799

Outcomes in Patients with Early and Delayed Onset Lupus Nephritis
Abstract Number: 2805

Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
Abstract Number: 21

Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Abstract Number: 7L

Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Abstract Number: 2870

Overexpression of EZH2 at the microRNA-142 Regulatory Region Contributes to Down-Regulation of microRNA-142-3p/5p in Systemic Lupus Erythematosus
Abstract Number: 798

Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].